Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948951 | 0.98 | GRM2 (0.49) | GRM2LTB4RLTB4R2KDM4EFFAR4 | |
| SCHEMBL13506327 | 0.89 | LMNA (0.56) | GRM2KDM4EFFAR4ALDH1A1LMNA | |
| SCHEMBL13492009 | 0.87 | KDM4E (0.60) | LTB4RLTB4R2KDM4EPPARAALDH1A1 | |
| SCHEMBL1006920 | 0.87 | KDM4E (0.60) | LTB4RLTB4R2KDM4EPPARAALDH1A1 | |
| SCHEMBL1009647 | 0.86 | FFAR1 (0.44) | LTB4RLTB4R2FFAR4CNR2PPARA | |
| SCHEMBL8220579 | 0.85 | KDM4E (0.61) | LTB4RKDM4EPPARAALDH1A1LMNA | |
| SCHEMBL4951982 | 0.84 | FFAR4 (0.45) | FFAR4CNR2PPARA | |
| SCHEMBL8163174 | 0.81 | LMNA (0.62) | LTB4RLTB4R2CNR2PPARAFABP3 | |
| SCHEMBL8162525 | 0.81 | LMNA (0.62) | LTB4RLTB4R2CNR2PPARAFABP3 | |
| SCHEMBL8148742 | 0.81 | LMNA (0.62) | LTB4RLTB4R2CNR2PPARAFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | GRM2 1610/4885LTB4R 909/4885LTB4R2 606/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | GRM2 1610/4885LTB4R 909/4885LTB4R2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.